Iovance Biotherapeutics, Inc. Forecasted to Post FY2026 Earnings of ($1.03) Per Share (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc. (NASDAQ:IOVAFree Report) – Equities research analysts at Zacks Research issued their FY2026 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a research note issued to investors on Wednesday, March 20th. Zacks Research analyst S. Ganoria anticipates that the biotechnology company will post earnings per share of ($1.03) for the year. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.41) per share.

Other research analysts also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of Iovance Biotherapeutics in a research note on Thursday, February 29th. The Goldman Sachs Group lifted their target price on Iovance Biotherapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Chardan Capital lifted their target price on Iovance Biotherapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research note on Tuesday, February 20th. Wells Fargo & Company lifted their target price on Iovance Biotherapeutics from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, March 1st. Finally, Piper Sandler lifted their target price on Iovance Biotherapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Thursday, March 14th. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $24.64.

Check Out Our Latest Stock Report on Iovance Biotherapeutics

Iovance Biotherapeutics Stock Down 2.2 %

NASDAQ:IOVA opened at $15.02 on Thursday. The stock’s 50 day moving average price is $11.82 and its 200 day moving average price is $7.79. The company has a market capitalization of $4.20 billion, a PE ratio of -7.99 and a beta of 0.63. Iovance Biotherapeutics has a 52-week low of $3.21 and a 52-week high of $18.33.

Iovance Biotherapeutics (NASDAQ:IOVAGet Free Report) last issued its earnings results on Wednesday, February 28th. The biotechnology company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.01). The firm had revenue of $0.48 million during the quarter, compared to analyst estimates of $1.44 million. During the same quarter in the previous year, the business earned ($0.64) earnings per share.

Institutional Investors Weigh In On Iovance Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of IOVA. China Universal Asset Management Co. Ltd. lifted its stake in shares of Iovance Biotherapeutics by 116.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 6,356 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 3,414 shares in the last quarter. Comerica Bank acquired a new position in shares of Iovance Biotherapeutics in the third quarter worth about $30,000. Annandale Capital LLC acquired a new position in shares of Iovance Biotherapeutics in the third quarter worth about $32,000. Clear Street Markets LLC acquired a new position in shares of Iovance Biotherapeutics in the third quarter worth about $35,000. Finally, KBC Group NV acquired a new position in shares of Iovance Biotherapeutics in the fourth quarter worth about $37,000. Hedge funds and other institutional investors own 81.85% of the company’s stock.

Insider Activity at Iovance Biotherapeutics

In other Iovance Biotherapeutics news, Director Merrill A. Mcpeak bought 250,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was purchased at an average cost of $9.15 per share, for a total transaction of $2,287,500.00. Following the completion of the purchase, the director now owns 320,150 shares of the company’s stock, valued at approximately $2,929,372.50. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 10.40% of the company’s stock.

Iovance Biotherapeutics Company Profile

(Get Free Report)

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.

Featured Stories

Earnings History and Estimates for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.